The NHS has confirmed that a controversial trial of puberty-blocking drugs for children who identify as transgender will go ahead, despite a court challenge. The Medicines and Healthcare products Regulatory Agency (MHRA) announced on Friday that the trial can proceed with minimum age limits of 11 for girls and 12 for boys. This represents a compromise from the suggested age limit of 14 that the MHRA raised in February.
Legal Challenge and Opposition
James Esses, a psychologist and campaigner behind the legal challenge, has appealed to Health Secretary James Murray to “pull the plug on this monstrosity.” He stated, “We have no choice but to seek an emergency injunction to block a single child being recruited and given this poison.”
Helen Joyce, of the charity Sex Matters, expressed disappointment, saying, “It appears that gender ideology has broken yet another institution. The MHRA’s mission is supposedly to ‘put patients first’ in everything it does, and yet it is signing off on a trial that does the opposite. It is already clear that puberty blockers are no solution to childhood gender distress, and that they cause unacceptable harm.”
Trial Safeguards and Requirements
Under the trial, no child will be able to participate without parental consent. Young people must also meet all other eligibility criteria, including “demonstrating a good understanding of the intervention and its possible benefits and risks.” The researchers stated that they “always welcome scrutiny” of studies involving children and young people and that, in addition to setting a minimum age, they have strengthened patient information. However, they noted that “there are no major changes to the design or conduct” of the trial.
Concerns from Medical and Political Figures
Dr. Louise Irvine, a GP and co-chair of the Clinical Advisory Network on Sex and Gender, said, “I am surprised and disappointed that the regulators have once again approved this trial. It will put children at risk of harm for no clear benefit – it is risky, badly designed, unethical and unnecessary.”
Conservative Party MP Rebecca Paul added, “I am deeply concerned by the decision to restart the Pathways trial and to allow children as young as 11 and 12 to be given puberty blockers. No child can meaningfully consent to interventions that may have lifelong consequences for their health, sexual function and fertility. Most young people referred to gender identity services are among the most vulnerable. They deserve compassionate, evidence-based care, not to be turned into test subjects. I will continue to do all I can to oppose this trial and to ensure that the safety and protection of children is put ahead of ideology and pressure from activists.”
